Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Ipopema Benefit 3 Fizan Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | zł125.00 |
52 Week High | zł125.00 |
52 Week Low | zł125.00 |
Beta | 0 |
1 Month Change | 0% |
3 Month Change | n/a |
1 Year Change | n/a |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | 10.77% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
IPOBENE3E | PL Capital Markets | PL Market | |
---|---|---|---|
7D | 0% | 2.7% | -1.0% |
1Y | n/a | 51.4% | 25.0% |
Return vs Industry: Insufficient data to determine how IPOBENE3E performed against the Polish Capital Markets industry.
Return vs Market: Insufficient data to determine how IPOBENE3E performed against the Polish Market.
Price Volatility
IPOBENE3E volatility | |
---|---|
IPOBENE3E Average Weekly Movement | n/a |
Capital Markets Industry Average Movement | 5.2% |
Market Average Movement | 5.3% |
10% most volatile stocks in PL Market | 9.5% |
10% least volatile stocks in PL Market | 3.3% |
Stable Share Price: IPOBENE3E has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine IPOBENE3E's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | n/a | n/a | n/a |
Ipopema Benefit 3 Fizan Fundamentals Summary
IPOBENE3E fundamental statistics | |
---|---|
Market cap | n/a |
Earnings (TTM) | zł0 |
Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs IPOBENE3E overvalued?
See Fair Value and valuation analysisEarnings & Revenue
IPOBENE3E income statement (TTM) | |
---|---|
Revenue | zł0 |
Cost of Revenue | zł0 |
Gross Profit | zł0 |
Other Expenses | zł0 |
Earnings | zł0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did IPOBENE3E perform over the long term?
See historical performance and comparison